Chris Paszty
Overview
Explore the profile of Chris Paszty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nioi P, Taylor S, Hu R, Pacheco E, He Y, Hamadeh H, et al.
J Bone Miner Res
. 2015 Feb;
30(8):1457-67.
PMID: 25678055
Sclerostin antibody (Scl-Ab) increases bone formation through a process dependent on the activation of canonical Wnt signaling, although the specific signaling in the osteoblast lineage in vivo is largely unknown....
2.
Kedlaya R, Veera S, Horan D, Moss R, Ayturk U, Jacobsen C, et al.
Sci Transl Med
. 2013 Nov;
5(211):211ra158.
PMID: 24225945
Osteoporosis pseudoglioma syndrome (OPPG) is a rare genetic disease that produces debilitating effects in the skeleton. OPPG is caused by mutations in LRP5, a WNT co-receptor that mediates osteoblast activity....
3.
Qian X, Yuan X, Vonderfecht S, Ge X, Lee J, Jurisch A, et al.
J Am Soc Nephrol
. 2012 Nov;
24(1):66-76.
PMID: 23184054
Wnt-modulator in surface ectoderm (WISE) is a secreted modulator of Wnt signaling expressed in the adult kidney. Activation of Wnt signaling has been observed in renal transplants developing interstitial fibrosis...
4.
Li C, Ominsky M, Tan H, Barrero M, Niu Q, Asuncion F, et al.
Bone
. 2011 Sep;
49(6):1178-85.
PMID: 21890008
Humans with inherited sclerostin deficiency have high bone mass. Targeted deletion of the sclerostin gene in mice (SOST-KO) causes increases in bone formation, bone mass and bone strength. Inhibition of...
5.
Li X, Ominsky M, Warmington K, Niu Q, Asuncion F, Barrero M, et al.
Endocrinology
. 2011 Jul;
152(9):3312-22.
PMID: 21733832
Clinical studies have revealed a blunting of the bone anabolic effects of parathyroid hormone treatment in osteoporotic patients in the setting of pre- or cotreatment with the antiresorptive agent alendronate...
6.
Ominsky M, Li C, Li X, Tan H, Lee E, Barrero M, et al.
J Bone Miner Res
. 2011 May;
26(5):1012-21.
PMID: 21542004
Therapeutic enhancement of fracture healing would help to prevent the occurrence of orthopedic complications such as nonunion and revision surgery. Sclerostin is a negative regulator of bone formation, and treatment...
7.
Tian X, Jee W, Li X, Paszty C, Ke H
Bone
. 2010 Sep;
48(2):197-201.
PMID: 20850580
Sclerostin monoclonal antibody (Scl-Ab) has been shown to increase bone mass and bone strength by stimulating bone formation in an ovariectomy-induced bone loss rat model. The purpose of this study...
8.
Li X, Warmington K, Niu Q, Asuncion F, Barrero M, Grisanti M, et al.
J Bone Miner Res
. 2010 Jul;
25(12):2647-56.
PMID: 20641040
The purpose of this study was to evaluate the effects of sclerostin inhibition by treatment with a sclerostin antibody (Scl-AbII) on bone formation, bone mass, and bone strength in an...
9.
Paszty C, Turner C, Robinson M
J Bone Miner Res
. 2010 Jun;
25(9):1897-904.
PMID: 20564241
No abstract available.
10.
Tian X, Setterberg R, Li X, Paszty C, Ke H, Jee W
Bone
. 2010 Jun;
47(3):529-33.
PMID: 20561907
The current report describes the skeletal effects of a sclerostin monoclonal antibody (Scl-AbIII) treatment at a yellow (fatty) marrow skeletal site in adult female rats. Ten-month-old female Sprague-Dawley rats were...